Stock Price Movement and Market Context
On 15 Dec 2025, Lincoln Pharmaceuticals recorded its lowest price in the past year at Rs.466.4. The stock traded within a narrow range of Rs.4.35 during the day, reflecting limited intraday volatility. This price level stands in stark contrast to its 52-week high of Rs.944.95, indicating a substantial reduction in market valuation over the last twelve months.
In comparison, the broader market, represented by the Sensex, opened lower at 84,891.75 points, down by 375.91 points or 0.44%, and was trading at 84,984.54 points (-0.33%) at the time. The Sensex remains close to its 52-week high of 86,159.02, just 1.38% away, supported by bullish moving averages with the 50-day moving average positioned above the 200-day moving average. Small-cap stocks led the market gains, with the BSE Small Cap index rising by 0.08% on the day.
Lincoln Pharmaceuticals underperformed its sector by 0.61% on the day, and its price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a sustained downward trend in the stock price relative to its recent history.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
See What's Driving the Rally →
Financial Performance Overview
Lincoln Pharmaceuticals’ financial results over the past year and longer term reveal subdued growth and profitability metrics. The company’s net sales have shown an annual growth rate of 9.21% over the last five years, while operating profit has grown at a rate of 5.37% during the same period. These figures indicate modest expansion in revenue and earnings before interest and taxes.
Recent quarterly results for September 2025 show a decline in profitability. Profit after tax (PAT) stood at Rs.19.98 crores, reflecting a fall of 24.1% compared to the previous corresponding period. Similarly, profit before tax excluding other income (PBT less OI) was Rs.21.58 crores, down by 12.98%. The return on capital employed (ROCE) for the half-year ended at 15.46%, marking the lowest level recorded in recent periods.
Over the past year, the company’s profits have fallen by 17.2%, aligning with the downward trend in its stock price. The one-year stock return for Lincoln Pharmaceuticals is -49.54%, significantly lagging behind the Sensex’s 3.48% gain over the same period. The stock has also underperformed the BSE500 index across the last three years, one year, and three months, indicating persistent challenges in market valuation relative to broader benchmarks.
Shareholding and Valuation Metrics
Despite Lincoln Pharmaceuticals’ size within the Pharmaceuticals & Biotechnology sector, domestic mutual funds hold no stake in the company. This absence of institutional ownership may reflect a cautious stance towards the stock’s valuation or business prospects.
The company maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. Its return on equity (ROE) stands at 11.2%, which is moderate within the sector context. The stock’s price-to-book value ratio is 1.3, suggesting that it is trading at a valuation considered fair relative to its book value and peer group historical averages.
These valuation metrics imply that while the stock price has declined sharply, the company’s underlying asset base and profitability ratios provide some measure of stability in valuation terms.
Is Lincoln Pharmaceuticals your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Sector and Industry Positioning
Lincoln Pharmaceuticals operates within the Pharmaceuticals & Biotechnology industry, a sector that has generally experienced steady demand and innovation-driven growth. However, the company’s stock performance contrasts with the broader sector trends, as it has underperformed its peers and the overall market indices.
The stock’s current trading below all major moving averages suggests that market participants are pricing in subdued near-term prospects. The narrow trading range observed on the day of the new 52-week low indicates limited buying interest at these levels, which may reflect ongoing caution among investors.
While the Sensex and small-cap indices have shown resilience and modest gains, Lincoln Pharmaceuticals’ share price trajectory highlights company-specific factors influencing market sentiment.
Summary of Key Metrics
To summarise, Lincoln Pharmaceuticals’ stock has reached Rs.466.4, its lowest level in the past year, representing a decline of over 50% from its 52-week high of Rs.944.95. The company’s financial data reveals modest sales growth over five years, recent declines in quarterly profits, and a moderate return on equity. The absence of domestic mutual fund ownership and the stock’s position below all key moving averages underscore the challenges faced by the company in the current market environment.
Despite these factors, the company’s low debt levels and fair valuation metrics provide some context for its current market standing within the Pharmaceuticals & Biotechnology sector.
Only ₹14,999 - Get MojoOne + Stock of the Week for 2 Years PLUS 6 Months FREE Claim 83% OFF →
